Stockscreener 앱 받기
44.51
0.95%
0.42
시간 외 거래:
44.09
-0.42
-0.94%
Alkermes Plc 주식(ALKS)의 최신 뉴스
Alkermes plc Stock (IE00B56GVS15): Orphan-Drug Boost For Sleep Disorder Candidate Alixorexton - AD HOC NEWS
Alkermes receives transatlantic orphan drug designations for alixorexton - grafa.com
Alkermes’ alixorexton receives orphan drug designations in US, EU - Investing.com
Alkermes (ALKS) wins orphan drug designations in U.S. and Europe for alixorexton - Stock Titan
New narcolepsy drug wins rare-disease backing in U.S., Europe - Stock Titan
Alkermes Plc (ALKS) Stock Analysis: Growth Potential With A 28.20% Revenue Surge - DirectorsTalk Interviews
Why (ALKS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Insider Sell: Christopher Wright Sells 2,000 Shares of Alkermes PLC (ALKS) - GuruFocus
Alkermes (ALKS) director sells 2,000 shares under Rule 10b5-1 plan - Stock Titan
Alkermes plc (ALKS) Rule 144 notice: 2,000 vested RSU shares listed - Stock Titan
Alkermes' alixorexton gains FDA orphan drug status for idiopathic hypersomnia - MSN
Alkermes (ALKS) Receives FDA Orphan Designation for Alixorexton - GuruFocus
Alkermes (ALKS) Receives Orphan Drug Designation for Alixorexton - GuruFocus
Alkermes touts orexin ambitions as Alixorexton enters phase 3 and CEO transition nears - MSN
Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears - Yahoo Finance
ALKS: Orexin agonist program advances with strong clinical data, strategic acquisition, and leadership transition - TradingView
ALKS: Orexin agonist advances, Avadel integration, and pipeline expansion drive strategic momentum - TradingView
Alkermes stock hits 52-week high at 44.58 USD By Investing.com - Investing.com Australia
Alkermes PLC (ALKS) Shares Surge 4.4% -- What GF Score of 74 Tel - GuruFocus
Alkermes Jumps 5.6% After RBC Capital Maintains Outperform - AlphaStreet
Alkermes stock hits 52-week high at 44.58 USD - Investing.com
ALKS Maintained by RBC Capital -- Price Target Raised to $56.00 - GuruFocus
Alkermes' Orexin May Have Applicability Outside Sleep, RBC Says - marketscreener.com
RBC Capital raises Alkermes stock price target on pipeline potential By Investing.com - Investing.com South Africa
RBC Capital raises Alkermes stock price target on pipeline potential - Investing.com India
RBC Raises Price Target on Alkermes to $56 From $45, Keeps Outperform Rating - marketscreener.com
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight - GlobeNewswire Inc.
ALKS Q1 2026 Earnings: EPS Surpasses Expectations Despite Net LossEarnings Beat Alert - newsline.com
Alkermes Plc (ALKS) Stock Analysis: Strong Buy Ratings And Promising Growth Potential - DirectorsTalk Interviews
Alkermes to participate in the Goldman Sachs 47th annual global healthcare conference - MSN
Should Alkermes’ Stronger Q1 2026 Results and Sleep-Medicine Advances Prompt Action From ALKS Investors? - Yahoo Finance
Alkermes to present new data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, highlighting breadth of sleep medicine research - MSN
Alkermes Public Limited Company Trade Ideas — XETR:8AK - TradingView
Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech - The Motley Fool
Insider Sell Alert: David Gaffin Sells Shares of Alkermes PLC - GuruFocus
ALKS Stock Surges 15% On Lilly-Centessa Buyout Igniting Sleep Pipeline Hopes - Stocktwits
Alkermes (ALKS) Showcases Sleep Medicine Research at SLEEP 2026 - GuruFocus
Alkermes (ALKS) EVP Gaffin sells 2,034 shares under 10b5-1 plan - Stock Titan
[144] Alkermes plc. SEC Filing - Stock Titan
Alkermes plc (ALKS) Stock Price, News, Quote & History - Yahoo Finance
Alkermes to Present Sleep Medicine Research at SLEEP 2026 - GuruFocus
Alkermes (ALKS) Up 21.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Alkermes to present narcolepsy drug data at SLEEP 2026 By Investing.com - Investing.com South Africa
Alkermes to present narcolepsy drug data at SLEEP 2026 - Investing.com
New narcolepsy and hypersomnia treatment data from Alkermes at SLEEP 2026 - Stock Titan
Alkermes PLC (ALKS) Shares Surge 3.5% -- What GF Score of 75 Tel - GuruFocus
ALKS Stock Price, Quote & Chart | ALKERMES PLC (NASDAQ:ALKS) - ChartMill
Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - Business Wire
Is Alkermes’ (ALKS) New LYBALVI Real-World Data Quietly Reframing Its Psychiatry Investment Story? - simplywall.st
Understanding Momentum Shifts in (ALKS) - Stock Traders Daily
1.13%
1.65%
자본화:
|
볼륨(24시간):